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Background: In many types of cancer, prostaglandin E2 (PGE2) is associated with tumour related processes
including proliferation, migration, angiogenesis and apoptosis. However in gliomas the role of this prostanoid is
poorly understood. Here, we report on the proliferative, migratory, and apoptotic effects of PGE1, PGE2 and
Ibuprofen (IBP) observed in the T98G human glioma cell line in vitro.
Methods: T98G human glioma cells were treated with IBP, PGE1 or PGE2 at varying concentrations for 24–72 hours.
Cell proliferation, mitotic index and apoptotic index were determined for each treatment. Caspase-9 and caspase-3
activity was measured using fluorescent probes in live cells (FITC-LEHD-FMK and FITC-DEVD-FMK respectively). The
migratory capacity of the cells was quantified using a scratch migration assay and a transwell migration assay.
Results: A significant decrease was seen in cell number (54%) in the presence of 50 μM IBP. Mitotic index and
bromodeoxyuridine (BrdU) incorporation were also decreased 57% and 65%, respectively, by IBP. The apoptotic
index was increased (167%) and the in situ activity of caspase-9 and caspase-3 was evident in IBP treated cells. The
inhibition of COX activity by IBP also caused a significant inhibition of cell migration in the monolayer scratch assay
(74%) and the transwell migration assay (36%).
In contrast, the presence of exogenous PGE1 or PGE2 caused significant increases in cell number (37% PGE1 and
45% PGE2). When mitotic index was measured no change was found for either PG treatment. However, the BrdU
incorporation rate was significantly increased by PGE1 (62%) and to a greater extent by PGE2 (100%). The apoptotic
index was unchanged by exogenous PGs. The addition of exogenous PGs caused an increase in cell migration in
the monolayer scratch assay (43% PGE1 and 44% PGE2) and the transwell migration assay (28% PGE1 and 68%
PGE2).
Conclusions: The present study demonstrated that treatments which alter PGE1 and PGE2 metabolism influence
the proliferative and apoptotic indices of T98G glioma cells. The migratory capacity of the cells was also
significantly affected by the change in prostaglandin metabolism. Modifying PG metabolism remains an interesting
target for future studies in gliomas.
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Malignant gliomas and especially Glioblastoma multi-
forme (GBM) are the most malignant and prevalent
intracranial tumours, classified as grade IV by the World
Health Organization (WHO). GBMs are characterized
by genetic alterations affecting genes that control cell
growth, migration, apoptosis, and invasion. Despite very
aggressive treatment including surgery and combined
radio and chemotherapy the median survival for most
patients with GBM is only 1 year. Therefore there is an
urgent need for the development of novel therapeutic
agents [1,2].
Non-steroidal anti-inflammatory drugs (NSAIDs) are
widely used in the treatment of pain, fever and inflam-
mation caused by various physiological or pathological
conditions. Clinical trials have demonstrated that long-
term NSAID use significantly reduces the risk of colo-
rectal cancer and other tumours such as breast, lung,
prostate and gastric cancer [3-5].
NSAIDs are known to inhibit a variety of cellular pro-
cesses including signal transduction, transcription, and
DNA repair. NSAIDs can alter cell cycle distribution, in-
hibit cyclins, modulate Bcl-2 family proteins and induce
apoptosis [6,7]. NSAIDs also inhibit angiogenesis, an im-
portant factor necessary for tumour growth and survival,
suggesting a rationale for their potential therapeutic ap-
plication as anticancer agents [8].
The mechanism by which NSAIDs exert their anti-
inflammatory activity is primarily by inhibiting the syn-
thesis of prostaglandins through inhibition of both
cyclooxygenase isoforms (COX-1 and COX-2), the rate-
limiting enzyme of the cascade. COX-1 is constitutively
expressed in many tissues and plays an important role in
the control of homeostasis. Conversely, COX-2 is an indu-
cible enzyme and is activated in response to extracellular
stimuli such as growth factors and pro-inflammatory cyto-
kines [9,10].
Several studies have shown COX and PGs play a role
in cell growth, survival, migration/invasion and angio-
genesis of tumour cells. Accumulating evidence suggests
that the increase in overexpression of COX-2 and PGE2
in human glioma is associated with poor prognosis and
tumour progression [11,12].
Ibuprofen (IBP) belongs to the group of NSAIDs, and
is a potent COX-1 and COX-2 inhibitor. Besides its
widespread use in the treatment of inflammatory dis-
eases, it has been shown that IBP may be effective in the
treatment and/or prevention of cancers including pros-
tate and colorectal cancer [13-15].
However, the effect of IBP treatment in GBM has not
been widely investigated. Recent studies from our la-
boratory have shown novel ruthenium-containing IBP
complexes have significant effects on glioma cell prolif-
eration and apoptosis [16,17]. In this study, we aimed toassess the potential effects of IBP on tumour cell prolif-
eration, migration and apoptosis in T98G human glioma
cells. The effect of the addition of exogenous PGE1 and
PGE2 to the cells was also studied. PGE1 was compared
with PGE2 as it has been reported to interact not only
with the EP receptors EP3 and EP4 but also with the IP
receptor, while PGE2 can interact with all four EP recep-
tors. The cellular response to PGE1 and PGE2 depends
on both the expression of receptors and the synthetic
capacity of the individual tissue [18].
The study aimed to test the importance of PGE1 and
PGE2 metabolism to the proliferative and apoptotic indi-
ces of T98G glioma cells. Since prostanoids are also
involved in cell migration the effect of IBP, PGE1 and
PGE2 on the migratory capacity of the cells was investi-
gated using two migration assays.
Methods
Cell culture
T98G cells, derived from a human glioblastoma, were
obtained from the ATCC and donated by Prof. S.S.
Maria-Engler. Cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS), 50U/ml penicillin, and 50 μg/ml
streptomycin. Cells in the exponential phase of growth
were used, growing in 75 cm2 flasks in a humidified at-
mosphere of 5% CO2, 95% air at 37°C. After growth to
the desired density cells were washed with PBS and tryp-
sinized (trypsin 0.025%/ EDTA 0.02%) for subsequent
plating. All experiments used cells grown in DMEM
with FCS and antibiotics as stated above.
Drug treatment
Ibuprofen (Cayman Chemicals) was dissolved in ethanol
to achieve the stock concentrations desired. PGE1 and
PGE2 (Cayman Chemicals) were dissolved in dimethyl
sulfoxide (DMSO; Sigma-Aldrich). All drugs were fur-
ther diluted in DMEM (Gibco BRL) to their final
concentration.
Cell proliferation assay
The cells were treated with IBP (25–200 μM), PGE1
(0.01–10 μM) or PGE2 (0.01–10 μM) for up to 72 hours
in 75 cm2 flasks. After that, the cells were harvested with
trypsin (trypsin 0.025%/ EDTA 0.02%) and the cell num-
ber was determined in an improved Neubauer counting
chamber [19]. The cell proliferation assay was conducted
three times for each concentration.
Analysis of nuclear morphology
The IBP, PGE1 or PGE2 treated and control cells were
fixed in situ with 4% formaldehyde in 0.1 M potassium
phosphate buffer at pH 7.2. The cells were washed (x3)
with PBS, pH 7.2, and incubated with 5 μg/ml Hoechst
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examined and immediately photographed using a fluor-
escence microscope (Nikon Optiphot-II epifluorescence
microscope equipped with, a Cool Snap Pro camera, and
Image Pro plus software). Apoptotic cells can be distin-
guished from viable cells by their nuclear morphology
with nuclear condensation and fragmentation, as well as
by the higher intensity of blue fluorescence of the nuclei.
The mitotic index was determined by the number of
cells in cell division. A total of 200 cells were counted in
multiple randomly selected fields, and the percentage of
apoptotic and mitotic index cells were then calculated
per total cell number.
Migration assay
Cells were plated into 30 mm petri dishes (1.5 x 105/
dish) and maintained in a humidified atmosphere of 5%
CO2: 95% air at 37°C. During the given period of
48 hours, the cells were treated daily with IBP (25 μM
and 50 μM), PGE1 (10 μM) or PGE2 (10 μM). Before the
end of treatment, the cell layer was scraped with a sterile
razor blade (marking the point of zero migration) and
the petri dish returned to the incubator for a further
10 hours in the presence of treatments. At the end of
this 10 hours incubation period, the cells were fixed in
situ with 4% formaldehyde in 0.1 M potassium phos-
phate buffer at pH 7.2. The cells were washed (x3) with
PBS, pH 7.2, and incubated with 5 μg/ml Hoechst 33342
for 5 min at room temperature. The samples were
washed (x3) with PBS, pH 7.2, before mounting in Slow-
Fade mounting medium. Cells were analyzed with a
Nikon Optiphot-II epifluorescence microscope equipped
with, a Cool Snap Pro camera, and Image Pro plus soft-
ware. The results were expressed as the number of mi-
grating cells per mm2 of scratched area of petri dish
[20].
Transwell migration assay
A second migration assay was performed using the 24-
well Boyden chamber plate with 8-μm pore size polycar-
bonate membrane filters. T98G cells (5 × 104/well) were
placed in the upper part of the Boyden chamber contain-
ing DMEM and 10% FCS, the lower chamber also con-
tained DMEM and 10%FCS. After a period of cell
adhesion (12 h) the medium was changed and treatment
(IBP, PGE1 and PGE2) was added to both parts of the
chamber. The culture media with treatment was chan-
ged daily for 48 h. After incubation, the cells on the
membrane filter were fixed with methanol and stained
with 0.05% crystal violet for 30 min.
The cells on the upper surface of the filter were
removed with a cotton swab. The membranes were then
rinsed in PBS until excess stain was removed. The mem-
branes were then were air-dried for 20 min. Themigratory cells were determined by counting the cells
that migrated to the lower side of the filter by bright
field microscopy at 200× magnification. Five random
fields were counted for each filter, and each sample was
assayed in triplicate.
5-Bromodeoxyuridine incorporation (BrdU)
BrdU incorporation assay (5-Bromodeoxyuridine incorp-
oration) was used to evaluate the synthesis of DNA.
T98G cells were seeded in 6-well plates (5 × 104/well),
followed by treatments for 72 h, as indicated. Cells were
then incubated with 10 μM BrdU from 45 min, followed
by fixation in 4% formaldehyde. After this, cells were
washed with PBS/ 0.2% Triton and incubated with 2 M
HCl for 10 min at room temperature. At the end of
10 min, the cells were placed in an oven at 40°C for
20 min. The blocking of endogenous peroxidase activity
was carried out for 30 min with H2O2 (3%) in methanol/
H2O followed by washing. The blocking of nonspecific
sites was carried out with glycine and normal donkey
serum for 1 h. The cells were then incubated “overnight”
with primary anti-BrdU antibody. On the following day
cells were incubated for 90 minutes with biotinylated
secondary antibody and then washed again with PBS/
0.2% Triton. The secondary antibody was detected by in-
cubation with a streptavidin-biotinylated horseradish
peroxidase for 60 min and washed, before reaction with
3,30- diaminobenzidine (DAB)/H2O2. Cells were left in
the developing solution for 2–10 min, counter-stained
with 0.1% methyl green, dehydrated and mounted with
Permount. The samples were photographed at random
in five different fields and the percentage of BrdU posi-
tive cells was determined as a percentage of the total cell
population [21].
Caspase-9 and Caspase-3 activity assay
T98G cells were seeded in 12 well plates (5 × 104/well)
and incubated for 72 h with IBP, PGE1 or PGE2. After
this period the cells were harvested with trypsin and
centrifuged at 1500 rpm for 2 min. The pellet was
resuspended in culture medium with treatment, 1 μl
FITC-LEHD-FMK substrate for caspase-3 or 1 μl FITC-
DEVD-FMK substrate for caspase-9, and 1 μl Hoechst
33342 at 37°C. Cells were washed and resuspended in
caspase assay kit buffer. After mounting, the cells were
viewed and photographed in a fluorescence microscope
Nikon Optiphot-II equipped with a Cool Snap Pro cam-
era and Image Pro Plus software.
Statistical analysis
All data are presented as the mean ± SEM. Statistical
analysis was carried out with the Graphpad InStat soft-
ware. One-way ANOVA with a multiple comparison
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of p < 0.05 was considered to be significant.
Results
Effect of IBP on cell proliferation and apoptosis
To determine the importance of PGE1 and PGE2 to cell
proliferation, T98G cells were treated with IBP, PGE1 or
PGE2 for 72 h (Figure 1). Cell counting showed that the
cell number was time and dose dependently decreased
by IBP (Figure 1A). In contrast, the presence of PGE1 orA
B
C
Figure 1 Effect of IBP, PGE1 and PGE2 on T98G cell number. (A)
Cell number decreased dose and time dependently in the presence
of IBP. (B) and (C) Cell number increased dose and time
dependently in the presence of PGE1 and PGE2. Data are from
three independent experiments in triplicate. Statistical significance,
* p < 0.05 vs control. These experiments were designed to
determine the concentrations and times of incubation for each
compound for the remainder of the study.PGE2 caused a time and dose dependent increase in cell
number (Figure 1B and 1C). Further experiments in the
study used the concentrations of 25 and 50 μM IBP,
10 μM PGE1 and 10 μM PGE2.
Cell counting showed that treatment with the lower
dose of IBP inhibited proliferation by 45% and at 50 μM
this inhibition increased to 54% (Figure 2A).
Additional experiments proved that longer periods of
exposure to IBP caused an even greater decrease in cell
number (Figure 3). Cell numbers at 5 days IBP were
decreased by 67.8% and 79.7% for 25 μM and 50 μM, re-
spectively. After 10 days IBP cell number were decreased
by 80.8% and 91.0% for 25 μM and 50 μM, respectively.
After 10 days IBP at 50 μM the decrease in cell number
(91.0%) reached levels greater than 3 days IBP at
200 μM (88.4%) (Figure 1A).
The fraction of cells in mitosis was quantified by cal-
culation of the mitotic index. The fraction of cells in mi-
tosis also decreased by 57% at 50 μM IBP (Figure 2B).
Similarly, the percentage of BrdU positive cells
decreased by 50% (25 μM IBP) and 65% (50 μM IBP)
(Figure 2C). The overall finding for cell proliferation was
an approximately 55–60% decrease in the presence of
50 μM IBP by the three methods used in the study.
The effects of IBP on apoptosis were analysed by
Hoechst 33342 nuclear staining and visualization of
caspase-9 and caspase-3 activity in live cells. Data from
Hoechst 33342 (Figure 4A) showed a higher percentage
of apoptotic nuclei in IBP cells compared to the control
group. Apoptosis increased by 167% in the presence of
50 μM IBP. Evidence of caspase-9 and caspase-3-like ac-
tivity was seen in the form of fluorescence substrate
cleavage only in the 50 μM IBP treated cells and repre-
sentative images are shown in Figure 4B-D.
Effect of IBP on cell migration
To investigate the effect of IBP on glioma cell migration
ability, scratch migration assays and transwell migration
assays were performed. As shown in Figure 5A-B, cell
migration in the scratch migration assay was reduced by
40% in cells treated with 25 μM ibuprofen and 74% in
cells treated with 50 μM IBP. Inhibition of migration was
also seen in the transwell assays with 36% inhibition at
50 μM compared with control cells (Figure 5C-D).
Effect of PGE1 and PGE2 on cell proliferation and
apoptosis
In the case of treatment with exogenous PGE1 and
PGE2, the results showed an increase of 37% with PGE1,
while PGE2 increased proliferation by 45% when com-
pared with the control (Figure 6A-B). When mitotic
index was measured the presence of PGE’s did not have
a significant effect (Figure 6C-D). However, the percent-



















Figure 2 Effect of IBP on cell number, mitotic index and
bromodeoxyuridine (BrdU) incorporation in T98G cells. (A) IBP
decreased cell number after 72 h at both 25 and 50 μM. Statistical
significance, *p = 0.0010 and **p = 0.0005, n = 3. (B) The number of
cells in mitosis was obtained by Hoechst 33342 staining, and
counting at x200 magnification. Statistical significance, *p = 0.0001,
n = 8. (C) The nuclear incorporation of BrdU in the S-phase was
measured after DAB staining and methyl green counterstaining.
Statistical significance, *p < 0.0011, n = 4. Each experiment was
















































Figure 3 Effect of IBP after 3, 5 and 10 days on T98G cell
number. (A-C) IBP decreased cell number after 3, 5 and 10 days
at both 25 and 50 μM. Statistical significance, *p = 0.0010 and
**p = 0.0005, n = 3.
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(Figure 6E-F).
The effect of PGE1 and PGE2 on apoptosis was also
analysed by Hoechst 33342 nuclear staining, and detec-
tion of caspase-9 and caspase-3 activity. Data from
Hoechst 33342 staining (Figure 6 G-H) showed no dif-
ference in the number of apoptotic cells. The presence
Control– Caspase 9
IBP 50µM – Caspase 9





Figure 4 Effect of IBP on apoptosis of T98G cells. (A)
Morphological changes in the nuclei typical of apoptosis were
analysed after staining with Hoechst 33342. An increase in apoptosis
was seen as both 25 and 50 μM. Statistical significance, *p = 0.0010
and ** p = 0.0001, n = 8. (B-D) Representative images of cleaved
substrates for caspase-9 and caspase-3 in live control and 50 μM IBP
treated cells. Cells with green fluorescence have activated caspase-9










Figure 5 Effect of IBP on T98G cell migration. (A) Migration of
T98G in the presence or absence of 25 μM or 50 μM IBP in the
monolayer scratch assay. Number of migrating cells per unit area.
Statistical significance, * p < 0.05 vs control, n = 8 in control, n = 16 in
25 μM and n = 16 in 50 μM. (B) Representative images of Hoechst
33342-labelled control and 50 μM IBP treated cells. Start point at
time zero indicated by line1 and average maximum migratory
distance possible in a 10 h period indicated by line 2. (C) Migration
of T98G in the presence or absence of 25 μM or 50 μM IBP in the
transwell assay. Number of migrating cells per x100 field. Statistical
significance, * p < 0.0005 vs control, n = 12. (D) Representative
images of crystal violet stained control and 50 μM IBP treated cells.
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cells was no different from the very low levels found in
the control cells, unlike the results found for IBP treated
cells (data not shown).
Effect of PGE1 and PGE2 on cell migration
Unlike IBP, the treatment with exogenous PGE1 and
PGE2 increased cell migration in both assays. PGE1
increased migration by 43% in the scratch migration
assay and by 28% in the transwell assay (Figure 7A-D).
PGE2 increased migration by 44% in the scratchmigration assay and by 68% in the transwell assay
(Figure 8A-D).
Discussion
Glioblastoma multiforme (GBM), a highly invasive and
vascularized tumour, responds poorly to conventional

















































































































































































Figure 6 Effect of PGE1 and PGE2 on cell number, mitotic index, bromodeoxyuridine (BrdU) incorporation and apoptosis in T98G cells.
(A) Both PGE1 and PGE2 increased cell number at 10 μM after 72 h treatment. Statistical significance *p = 0.0007 and **p = 0.0008, n = 4. (B) The
number of cells in mitosis was obtained by Hoechst 33342 staining, and counting at x200 magnification. n = 8. (C) The nuclear incorporation of
BrdU in the S-phase was measured after DAB staining and methyl green counterstaining. Statistical significance *p < 0.0001, n = 4. (D)
Morphological changes in the nuclei typical of apoptosis were analysed after staining with Hoechst 33342. Each experiment was repeated at least
three times.
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apoptosis in T98G human glioma cells. It has been
shown that several NSAIDs are able to induce glioma
cell apoptosis [22]. Previous studies have shown that invarious tumours a high concentration of PGE2 and a
high COX-2 activity are present. Overexpression of
COX-2/PGE2 in human tumors is associated with pro-

























































Figure 7 Effect of PGE1 on T98G cell migration. (A) Migration of T98G in the presence or absence of 10 μM PGE1 in the monolayer scratch
assay. Number of migrating cells per unit area. *p = 0.0001, n = 8 (B) Representative images of Hoechst 33342-labeled control and 10 μM PGE1
treated cells. Start point at time zero indicated by line1 and average maximum migratory distance possible in a 10 h period indicated by line 2.
(C) Migration of T98G in the presence or absence of 10 μM PGE1 in the transwell assay. Number of migrating cells per x100 field. Statistical
significance *p = 0.0001, n = 16. (D) Representative images of crystal violet stained control and 10 μM PGE1 treated cells.
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cells is still poorly defined.
IBP, a generic and relatively inexpensive, non-selective
COX inhibitor, is still widely used in clinical practice in
the treatment of various cancers including colon and
prostate cancer [3-5]. Despite enthusiasm about the po-
tential usefulness of NSAIDs as anticancer agents, little
has been reported about the effects of IBP on braintumours. Therefore, the aim of this study was to investi-
gate the effect of IBP upon the proliferation, migration
and apoptosis processes in glioma cells.
Studies demonstrated that the proliferation and inva-
sion of cultured glioma cell lines was inhibited in vitro
by the specific COX-2 inhibitor NS-398, suggesting a
functional role for COX-2/ PGE2 in glioma [26]. In our

























































Figure 8 Effect of PGE2 on T98G cell migration. (A) Migration of T98G in the presence or absence of 10 μM PGE2 in the monolayer scratch
assay. Number of migrating cells per unit area. *p = 0.0001, n = 8 (B) Representative images of Hoechst 33342-labeled control and 10 μM PGE2
treated cells. Start point at time zero indicated by line1 and average maximum migratory distance possible in a 10 h period indicated by line 2.
(C) Migration of T98G in the presence or absence of 10 μM PGE2 in the transwell assay. Number of migrating cells per x100 field. Statistical
significance *p = 0.0001, n = 16. (D) Representative images of crystal violet stained control and 10 μM PGE2 treated cells.
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dependently. These findings are compatible with a study
that showed that inhibition of COX activity and expres-
sion blocked the release of PGE2 from U87-MG human
glioma cells and this generated a decrease in theirproliferation [27]. In a recent study nano-prodrugs of
IBP caused a greater reduction in cell proliferation in
comparison with the nano-prodrugs of indomethacin or
naproxen in the U87-MG cell line [28]. PGE2 plays an
important role in the pathogenesis of endometriosis.
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migration as well as invasion of human endometrial epi-
thelial and stromal cells. Results of the study indicate
that selective inhibition of PGE2 receptors EP2 and EP4
suppresses expression and/or activity of matrix metallo-
proteinase (MMP2 and MMP9) proteins and increases
expression of tissue inhibitor of metalloproteinases
(TIMP1, TIMP2, TIMP3, and TIMP4) proteins and
thereby decreases migration [29]. In another study PGE2
treatment significantly increased cell adhesion, migra-
tion, and invasion in hepatocellular carcinoma (HCC)
cells. In addition, the effects of PGE2 were found to be
associated with focal adhesion kinase (FAK) activity [30].
Indomethacin treatment reduced PGE2 content in nor-
mal and tumour tissue colorectal cancer. This reduction
in tumour tissue PGE2 content was related to significant
alterations in the expression of several hundred genes
including genes related to cell cycle control and apop-
tosis [31]. Interestingly, indomethacin-loaded nanocap-
sules inhibited the growth of glioma cells in vitro and
the C6 rat glioma model in vivo [32,33].
Our results demonstrated that T98G glioma cells
showed signs of apoptosis after treatment with both con-
centrations of IBP. We found that after IBP treatment,
chromatin condensation and fragmentation were
increased in the nuclei. In a recent study, the treatment
of U87-MG glioma cells with IBP nano-prodrugs
(25 μM and 50 μM) resulted in a significant increase in
cell death [27]. In another study the NSAID aspirin
induced apoptosis by the inhibition of cyclin D1 and
Bcl-2 in the A172 glioblastoma cell line [34]. From these
studies it is apparent that inhibition of PG production
by NSAIDs causes the induction of apoptosis in glioma
cells.
In conclusion, our results demonstrated that IBP treat-
ment suppressed T98G human glioma cell proliferation
and apoptosis in vitro. In addition IBP caused a signifi-
cant inhibition of T98G migration. In contrast, the
addition of either exogenous PGE1 or PGE2 caused a sig-
nificant increase in cell proliferation and increased cell
migration. The difference in PGE1 and PGE2 effects on
cell migration may be related to the expression profile of
EP and IP receptors in the T98G cell line and requires
further investigation. Altering prostaglandin metabolism
remains a promising target for GBM treatment and is
currently being studied in our laboratory.Competing interests
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